H.R.7184 amends the Controlled Substances Act to make it a federal crime to manufacture or distribute tableting machines, encapsulating machines, press punches, die systems, gelatin capsules, or related equipment/materials when the actor intends or knows those items will be used to produce controlled substances or listed chemicals and that the drugs will be unlawfully imported into the United States. The bill adds a new subsection to 21 U.S.C. 959 (codified here as section 1009 in the bill text), expands the list of prohibited acts, and creates tiered felony penalties tied to the type and scale of the conduct.
The statute reaches beyond U.S. territory: it targets actors who produce or ship illicit pill-pressing tools abroad with the purpose or reasonable cause to believe the controlled product will enter the U.S. market. It also directs the U.S. Sentencing Commission to update federal guidelines to reflect the new offenses.
For compliance officers, manufacturers, shippers, and prosecutors, the bill replaces a gap—tools and consumables for illicit pill production become an explicit enforcement focus, with specific mens rea language and quantity thresholds that trigger higher penalties.
At a Glance
What It Does
The bill inserts a new criminal prohibition into the Controlled Substances Act that bars manufacturing or distribution of pill presses, encapsulating machines, press punches, die systems, gelatin capsules, and related items where the actor intends or knows the items will be used to make controlled substances that will be unlawfully imported into the U.S., or has reasonable cause to believe so. It also revises the prohibited-acts section to add the new offense and establishes tiered maximum prison terms tied to the conduct and scale.
Who It Affects
Overseas and domestic manufacturers and distributors of tableting and encapsulating equipment, capsule producers, international shippers and freight forwarders, online marketplaces that facilitate cross-border sales, and federal enforcement agencies (DEA, DOJ, CBP). Health-care providers and communities affected by synthetic pill overdoses are indirect stakeholders because the law targets supply chains that feed illicit importation.
Why It Matters
This is a targeted attempt to choke off the supply of machinery and materials used to produce counterfeit synthetic drugs destined for the U.S., extending liability to actors outside the country when they have the requisite intent or reasonable cause to believe of unlawful import. The bill transforms a set of tools—previously a regulatory blind spot—into explicitly prosecutable conduct and sets clear criminal exposure and sentencing consequences.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill adds a new subsection to the Controlled Substances Act focused squarely on the tools of illicit pill and capsule production. It names specific items—tableting machines, encapsulating machines, press punches, die systems, gelatin capsules—and then reaches broadly to ‘‘any equipment, chemical, product, or material’’ that will be used to manufacture controlled substances or listed chemicals.
The key hook is not merely possession or sale; the statute criminalizes those acts when the actor intends or knows the item will be used to make illegal drugs and that those drugs will be unlawfully imported into the United States, or when the actor has reasonable cause to believe that outcome.
To operationalize that reach, the bill changes the prohibited-acts section of the CSA to cross-reference the new subsection and creates a standalone criminal offense for violating it. The penalty structure is graduated: certain violations carry up to 8, 10, or 20 years, and the bill raises the maximum to 15 years when the conduct involves large-scale shipments—defined as more than 1,000 kilograms of a chemical or product or more than 100 tableting/encapsulating machines.
Those numeric thresholds are the gate to enhanced sentences and will be focal points in investigations and indictments.Crucially, the bill uses three alternative mental-state standards—intending, knowing, or having reasonable cause to believe—which lowers the bar for prosecutors compared with an intent-only offense. That design makes it easier to pursue foreign manufacturers, online sellers, or intermediaries when factual circumstances (bulk orders, shipping patterns, buyer profiles) suggest likely misuse.
The measure also asks the U.S. Sentencing Commission to revise federal guidelines so sentence ranges and policy statements align with the new statutory penalties.The statute does not create a licensing or registration regime, nor does it establish express safe harbors for sales to vetted buyers. It therefore relies on criminal enforcement and traditional evidence-gathering to separate legitimate commercial activity from shipments intended to support illicit drug importation.
Because the bill extends liability to conduct tied to unlawful importation, enforcement will typically intersect with customs and border investigations and may require international cooperation to obtain evidence and effect arrests or prosecutions.
The Five Things You Need to Know
The bill adds a new offense to 21 U.S.C. 959 that specifically names tableting machines, encapsulating machines, press punches, die systems, gelatin capsules, and broadly any ‘‘equipment, chemical, product, or material’’ used to manufacture controlled substances destined for unlawful importation.
Prosecutors can proceed on three alternative mental states: the actor must have intended, known, or have had reasonable cause to believe the goods would be used to make controlled substances and unlawfully imported into the United States.
The statute creates tiered maximum prison terms: certain violations carry up to 8 years, up to 10 years, or up to 20 years depending on the offense category; offenses involving more than 1,000 kilograms of a chemical/product or more than 100 tableting/encapsulating machines raise the maximum to 15 years.
The bill revises the CSA prohibited-acts section to add the new manufacturing/distribution offense as a standalone covered violation—meaning standard criminal enforcement tools and forfeiture authorities applicable to CSA offenses can be deployed.
Section 2(c) directs the U.S. Sentencing Commission, under 28 U.S.C. 994(p), to review and amend federal sentencing guidelines and policy statements to reflect the new offenses and penalties.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title: ‘‘Preventing Rogue Equipment for Synthetic Substances Act’’ (PRESS Act)
A single-line provision that gives the bill its name. This is purely stylistic but signals the bill’s focus on equipment used to produce synthetic pills and capsules destined for illicit importation.
Creates an extraterritorial prohibition on manufacturing or distribution of specified equipment/materials
The bill inserts a new subsection that makes it unlawful to manufacture or distribute listed machinery, parts, capsules, or any equipment/chemical/product/material when the actor intends or knows it will be used to make a controlled substance or listed chemical and that the resultant drug will be unlawfully imported into the United States. It explicitly uses three mental-state alternatives—intend, know, or reasonable cause to believe—broadening prosecutorial pathways. This provision is written to apply even where the actor is outside the U.S., provided the statutory mens rea is proven.
Adds the new offense to the prohibited-acts list and establishes graduated maximum penalties
The bill amends the prohibited-acts section to list manufacturing/distributing the specified items in violation of the new subsection as a punishable offense. It replaces older cross-references and adds a new subsection (e) that sets maximum prison terms tied to different violation categories and creates an enhanced maximum (15 years) when the offense involves more than 1,000 kilograms of chemical/product or more than 100 tableting/encapsulating machines. Prosecutors will have statutory sentencing caps they can seek based on factual proof of scale and category.
Sentencing Commission review
Directs the U.S. Sentencing Commission, under its statutory authority, to update federal sentencing guidelines and policy statements to reflect the new offenses and statutory maximums. This is a delegation for guideline alignment rather than a directive that sets specific guideline levels; the Commission must determine appropriate offense levels and policy statements consistent with the new statutory scheme.
This bill is one of many.
Codify tracks hundreds of bills on Criminal Justice across all five countries.
Explore Criminal Justice in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Federal law enforcement (DEA, DOJ) — Gains a clear statutory basis to pursue producers and distributors of pill presses and related items when those goods are connected to illicit importation, expanding tools for indictments and asset-based investigations.
- Customs and Border Protection (CBP) and port authorities — Can coordinate with prosecutors under an express legal framework to block shipments and build cases against foreign and domestic suppliers who funnel equipment used to produce counterfeit pills.
- Communities and health systems affected by synthetic-pill overdose spikes — Stand to benefit indirectly if enforcement reduces the flow of counterfeit pills containing fentanyl or other dangerous synthetics into U.S. markets.
- Legitimate domestic manufacturers of compliant equipment — May see reduced illicit competition from overseas suppliers who previously sold devices into illicit supply chains without U.S. accountability.
Who Bears the Cost
- Overseas and domestic manufacturers and exporters of tableting/encapsulating equipment and gelatin capsules — Face criminal exposure and will need stronger buyer vetting, recordkeeping, and compliance controls to avoid ‘‘reasonable cause to believe’’ liability.
- Online marketplaces and freight-forwarders — Will confront increased compliance burdens and operational risk as intermediaries in cross-border transactions that could be secondarily involved with unlawful exportation.
- Small equipment suppliers and research labs using dual‑use machinery — Risk chilling effects and higher transaction costs because the statute does not provide express safe harbors or a clear licensing pathway for legitimate exports.
- Federal prosecutors and courts — Will absorb additional workload from extraterritorial investigations that require international evidence-gathering, complex jurisdictional proofs, and potentially lengthy forfeiture or asset-tracing litigation.
Key Issues
The Core Tension
The central dilemma is straightforward: the bill aggressively targets the supply chain for counterfeit synthetic pills to protect public health, but doing so by criminalizing the manufacture and distribution of dual‑use tools risks ensnaring lawful commerce, imposing heavy compliance costs, and creating difficult cross‑border prosecution and evidence challenges that may blunt practical enforcement.
The bill’s prosecutorial utility hinges on a trio of mental-state alternatives—intent, knowledge, or ‘‘reasonable cause to believe’’—which lowers the threshold to bring charges but also raises important evidentiary questions. Prosecutors can point to circumstantial indicia (bulk shipments, opaque supply chains, buyer profiles) to satisfy ‘‘reasonable cause,’’ but defendants will likely litigate the line between suspicious commerce and legitimate business.
That dispute will define both enforcement outcomes and compliance costs for manufacturers and intermediaries.
The extraterritorial sweep is operationally ambitious but practically constrained. U.S. authorities can indict foreign manufacturers, but effective prosecution will often require cooperation from foreign governments, assistance in obtaining evidence, or extradition—none of which the bill changes.
Moreover, the statute’s broad phrasing—‘‘any equipment, chemical, product, or material’’—and the lack of a licensing/safe‑harbor mechanism create a risk of overbreadth and a chilling effect on dual‑use trade. Small suppliers and research institutions may curtail legitimate sales rather than risk criminal exposure, shifting the problem to regulatory gray markets and making enforcement more difficult.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.